Octagon Capital Advisors LP 13F holdings, Q4 2025
Holdings as of December 31, 2025 · filings on SEC EDGAR · latest filing →
Octagon Capital Advisors LP disclosed 26 US equity positions worth $798.8m in its Q4 2025 13F filing. The largest position was ABVX at 12.8% of the reported book, followed by DNTH and COGT. Against the Q3 2025 filing, it opened 7 new positions, added to 2 and reduced 8 among the top 26 holdings.
What did Octagon Capital Advisors LP own in Q4 2025? Top 26 positions
| # | Stock | Sector | Weight | Value | Shares | Δ shares | vs Q3 2025 |
|---|---|---|---|---|---|---|---|
| 1 | ABVX ABIVAX SA | 12.8% | $102.0m | 756,000 | -43% | reduced | |
| 2 | DNTH DIANTHUS THERAPEUTICS INC | Healthcare | 12.5% | $99.6m | 2,416,667 | 0% | held |
| 3 | COGT COGENT BIOSCIENCES INC | Healthcare | 10.5% | $83.5m | 2,350,000 | -18% | reduced |
| 4 | TSHA TAYSHA GENE THERAPIES INC | Healthcare | 6.1% | $48.7m | 8,859,911 | -2% | reduced |
| 5 | GOSS GOSSAMER BIO INC | Healthcare | 5.4% | $43.1m | 13,915,371 | -18% | reduced |
| 6 | KYMR KYMERA THERAPEUTICS INC | Healthcare | 5.2% | $41.6m | 535,000 | 49% | added |
| 7 | AVBP ARRIVENT BIOPHARMA INC | 5.0% | $39.7m | 1,971,054 | 0% | held | |
| 8 | TRVI TREVI THERAPEUTICS INC | Healthcare | 4.4% | $35.2m | 2,815,000 | 0% | held |
| 9 | OCUL OCULAR THERAPEUTIX INC | Healthcare | 4.0% | $31.9m | 2,623,600 | -0% | held |
| 10 | BRD1EUR MIND MEDICINE MINDMED INC | 3.7% | $29.9m | 2,230,000 | 5% | added | |
| 11 | ALMS ALUMIS INC | 3.1% | $24.7m | 2,530,700 | – | new | |
| 12 | PALI PALISADE BIO INC | Healthcare | 2.8% | $22.5m | 9,567,898 | – | new |
| 13 | CDTX CIDARA THERAPEUTICS INC | 2.8% | $22.1m | 100,000 | 0% | held | |
| 14 | BIOA BIOAGE LABS INC | 2.6% | $21.1m | 1,598,000 | – | new | |
| 15 | 4XC1 KALVISTA PHARMACEUTICALS INC | 2.6% | $20.6m | 1,273,333 | 0% | held | |
| 16 | RAPT RAPT THERAPEUTICS INC | 2.4% | $19.4m | 574,000 | – | new | |
| 17 | CNTA CENTESSA PHARMACEUTICALS PLC | 2.3% | $18.8m | 750,000 | -10% | reduced | |
| 18 | PHVS PHARVARIS N V | 2.3% | $18.6m | 671,465 | -7% | reduced | |
| 19 | LXEO LEXEO THERAPEUTICS INC | Healthcare | 2.1% | $17.1m | 1,725,000 | – | new |
| 20 | BBOT BRIDGEBIO ONCOLOGY THERAPEUT | 1.6% | $13.1m | 1,043,110 | 0% | held | |
| 21 | DBVT DBV TECHNOLOGIES S A | 1.4% | $11.0m | 574,200 | -44% | reduced | |
| 22 | EVMN EVOMMUNE INC | 1.1% | $8.6m | 500,000 | – | new | |
| 23 | DTIL PRECISION BIOSCIENCES INC | 1.0% | $8.0m | 1,917,995 | – | new | |
| 24 | CRBP CORBUS PHARMACEUTICALS HLDGS | Healthcare | 1.0% | $7.8m | 955,000 | -14% | reduced |
| 25 | UNCY UNICYCIVE THERAPEUTICS INC | 0.7% | $5.8m | 1,000,000 | 0% | held | |
| 26 | PEPG PEPGEN INC | Healthcare | 0.6% | $4.6m | 700,000 | 0% | held |
Weights are shares of the reported long US equity book (options excluded). Values are as filed, normalised to whole dollars. Share changes compare against the immediately preceding filing only.